Kevin Feeley Sells 1,266 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,266 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $53.77, for a total value of $68,072.82. Following the sale, the chief financial officer owned 36,486 shares of the company’s stock, valued at approximately $1,961,852.22. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $25,554.48.
• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total value of $438,220.80.

GeneDx Stock Up 12.3%

NASDAQ WGS traded up $6.67 during trading hours on Thursday, hitting $60.99. The company had a trading volume of 1,870,647 shares, compared to its average volume of 1,047,962. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -22.76 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The firm’s 50 day moving average is $55.13 and its 200 day moving average is $91.01.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Sell-side analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. BTIG Research reduced their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $96.43.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about a class action lawsuit against GeneDx, with deadlines for lead plaintiff participation centered on August 3, 2026. WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The lawsuits allege GeneDx and executives made false or misleading statements about acquisition performance, reimbursement rates, and margin compression, and that investors were harmed after a sharp stock decline tied to the Q1 2026 earnings report. GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman
• Neutral Sentiment: One potentially supportive signal came from filings showing Casdin Capital added to its GeneDx position, which may indicate some institutional confidence despite the legal overhang. Casdin Capital, Llc Acquires 150,000 Shares of GeneDx (NASDAQ:WGS) Stock

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp lifted its position in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in GeneDx during the 4th quarter worth $27,000. Fifth Third Bancorp acquired a new position in GeneDx during the 1st quarter worth $31,000. Quarry LP lifted its position in GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares during the last quarter. Finally, Ramirez Asset Management Inc. acquired a new position in GeneDx during the 4th quarter worth $33,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.